Latest Breaking News On - Bing kung - Page 1 : comparemela.com

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients

United statesSan antonioUniversity of texasIntravesical cretostimogene grenadenorepvecCalmette guerinCretostimogene grenadenorepvecAmbaw belleteHenryb gonzBing kungMarkd tysonRobert svatekAmerican urological associationConvention centerGlobe newswire cg oncology incAnnual meetingChief operating officer

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesBing kungGoldman sachs coMorgan stanley coCalif business wire cg oncology incCantor fitzgerald coMorgan stanleyCg oncology incProspectus departmentCorporate developmentExchange commissionNasdaq global select marketGoldman sachsSci capitalCantor fitzgerald

CG Oncology Announces Pricing of Upsized Initial Public Offering

CG Oncology Announces Pricing of Upsized Initial Public Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesBing kungProspectus departmentCalif business wire cg oncology incMorgan stanleyExchange commissionCantor fitzgerald coCorporate developmentGoldman sachs coCg oncology incMorgan stanley coNasdaq global select marketGoldman sachsSci capitalCantor fitzgerald

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCretostimogene grenadenorepvecAndrea maddox smithBing kungAmbaw belleteDrug administrationCg oncology incCalif business wire cg oncology incBladder cancer advocacy networkCorporate developmentMeeting of the society urological oncologyBoth fast trackBreakthrough therapy designationFast track designationBacillus calmette guNon muscle invasive bladder cancer

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesCretostimogene grenadenorepvecBing kungAndrea maddox smithAmbaw belleteCg oncology incCorporate developmentMeeting of the society urological oncologyBladder cancer advocacy networkDrug administrationFast track designationBreakthrough therapy designationBacillus calmette guNon muscle invasive bladder cancerChief operating officerChief executive officer